July 17, 2024 03:16 AM EDTUpdated 06:46 AM
Deals
R&D
Pharma

Genen­tech parts ways with Re­lay Ther­a­peu­tics on SHP2 af­ter oth­er phar­ma ex­its

Kyle LaHucik

Senior Reporter

Roche’s Genen­tech is scrap­ping a col­lab­o­ra­tion and li­cense agree­ment with Re­lay Ther­a­peu­tics sur­round­ing the biotech’s clin­i­cal-stage oral SHP2 in­hibitor.

It’s the lat­est phar­ma­ceu­ti­cal com­pa­ny to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times